G1 THERAPEUTICS Company Profile (NASDAQ:GTHX)

About G1 THERAPEUTICS (NASDAQ:GTHX)

G1 THERAPEUTICS logoG1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GTHX
  • CUSIP: N/A
  • Web: www.g1therapeutics.com
Capitalization:
  • Market Cap: $699.49 million
  • Outstanding Shares: 28,285,000
Average Prices:
  • 50 Day Moving Avg: $18.63
  • 200 Day Moving Avg: $17.51
  • 52 Week Range: $12.04 - $28.67
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.66
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.37 per share
  • Price / Book: 5.66
Profitability:
  • EBIDTA: ($44,700,000.00)
Debt:
  • Current Ratio: 12.85%
  • Quick Ratio: 12.85%
Misc:
  • Average Volume: 80,419 shs.
  • Short Ratio: 10.41
 

Frequently Asked Questions for G1 THERAPEUTICS (NASDAQ:GTHX)

What is G1 THERAPEUTICS's stock symbol?

G1 THERAPEUTICS trades on the NASDAQ under the ticker symbol "GTHX."

How were G1 THERAPEUTICS's earnings last quarter?

G1 THERAPEUTICS (NASDAQ:GTHX) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.48. View G1 THERAPEUTICS's Earnings History.

When will G1 THERAPEUTICS make its next earnings announcement?

G1 THERAPEUTICS is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for G1 THERAPEUTICS.

Where is G1 THERAPEUTICS's stock going? Where will G1 THERAPEUTICS's stock price be in 2017?

4 analysts have issued 1-year price targets for G1 THERAPEUTICS's stock. Their predictions range from $23.00 to $34.00. On average, they expect G1 THERAPEUTICS's stock price to reach $29.75 in the next twelve months. View Analyst Ratings for G1 THERAPEUTICS.

Who are some of G1 THERAPEUTICS's key competitors?

Who are G1 THERAPEUTICS's key executives?

G1 THERAPEUTICS's management team includes the folowing people:

  • Seth A. Rudnick M.D., Chairman of the Board
  • Mark A. Velleca Ph.D., M.D., President, Chief Executive Officer, Director
  • Jay C. Strum Ph.D., Chief Scientific Officer
  • Jennifer K. Moses, Vice President - Finance and Administration
  • Rajesh K. Malik M.D., Chief Medical Officer
  • Gregory J. Mossinghoff, Chief Business Officer, Secretary
  • Andrew Philip Witty, Director
  • Fredric N. Eshelman Pharm.D., Independent Director
  • Glenn P. Muir, Independent Director
  • Tyrell J. Rivers, Independent Director

When did G1 THERAPEUTICS IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who owns G1 THERAPEUTICS stock?

G1 THERAPEUTICS's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include RA Capital Management LLC (181.37%), FMR LLC (132.09%), Franklin Resources Inc. (41.26%), Hillhouse Capital Management Ltd. (30.41%), Laurion Capital Management LP (13.51%) and Chartwell Investment Partners LLC (5.96%). Company insiders that own G1 THERAPEUTICS stock include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for G1 THERAPEUTICS.

Who bought G1 THERAPEUTICS stock? Who is buying G1 THERAPEUTICS stock?

G1 THERAPEUTICS's stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management LLC, FMR LLC, Franklin Resources Inc., Hillhouse Capital Management Ltd., Laurion Capital Management LP, Chartwell Investment Partners LLC, Vanguard Group Inc. and Goldman Sachs Group Inc.. Company insiders that have bought G1 THERAPEUTICS stock in the last two years include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 THERAPEUTICS.

How do I buy G1 THERAPEUTICS stock?

Shares of G1 THERAPEUTICS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is G1 THERAPEUTICS's stock price today?

One share of G1 THERAPEUTICS stock can currently be purchased for approximately $24.73.


MarketBeat Community Rating for G1 THERAPEUTICS (NASDAQ GTHX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about G1 THERAPEUTICS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for G1 THERAPEUTICS (NASDAQ:GTHX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.75 (20.30% upside)

Analysts' Ratings History for G1 THERAPEUTICS (NASDAQ:GTHX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
6/12/2017WedbushInitiated CoverageOutperform$31.00HighView Rating Details
6/12/2017Needham & Company LLCInitiated CoverageBuy -> Buy$34.00HighView Rating Details
6/12/2017J P Morgan Chase & CoInitiated CoverageOverweight -> Overweight$23.00HighView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for G1 THERAPEUTICS (NASDAQ:GTHX)
Earnings by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)
Earnings History by Quarter for G1 THERAPEUTICS (NASDAQ GTHX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017        
8/9/20176/30/2017($0.61)($1.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for G1 THERAPEUTICS (NASDAQ:GTHX)
2017 EPS Consensus Estimate: ($1.19)
2018 EPS Consensus Estimate: ($2.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171($0.58)($0.58)($0.58)
Q4 20171($0.61)($0.61)($0.61)
Q1 20181($0.52)($0.52)($0.52)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.61)($0.61)($0.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for G1 THERAPEUTICS (NASDAQ:GTHX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for G1 THERAPEUTICS (NASDAQ:GTHX)
Institutional Ownership Percentage: 35.10%
Insider Trades by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)
Institutional Ownership by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)
Insider Trades by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Clay ThorpMajor ShareholderBuy133,333$15.00$1,999,995.00View SEC Filing  
5/22/2017Fredric N EshelmanDirectorBuy300,000$15.00$4,500,000.00View SEC Filing  
5/22/2017Ra Capital Healthcare Fund LpInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for G1 THERAPEUTICS (NASDAQ:GTHX)
Latest Headlines for G1 THERAPEUTICS (NASDAQ:GTHX)
Source:
DateHeadline
bizjournals.com logoWhy Hatteras Venture Partners brought on Andrew Witty
www.bizjournals.com - September 20 at 5:22 AM
finance.yahoo.com logoG1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
finance.yahoo.com - September 18 at 6:48 PM
americanbankingnews.com logo Analysts Set $29.67 Target Price for G1 THERAPEUTICS (GTHX)
www.americanbankingnews.com - September 11 at 4:42 AM
nasdaq.com logoSRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGR
www.nasdaq.com - September 7 at 5:19 AM
americanbankingnews.com logo G1 THERAPEUTICS (GTHX) Given $29.67 Consensus Target Price by Brokerages
www.americanbankingnews.com - September 4 at 6:44 PM
americanbankingnews.com logo G1 THERAPEUTICS (GTHX) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - September 1 at 2:32 PM
bizjournals.com logoNCBiotech portfolio companies raise $128M in Q4
www.bizjournals.com - August 26 at 6:31 PM
finanznachrichten.de logoGainers & Losers Of Aug.21: CHRS, GTHX, OTIC, APEN, PETS...
www.finanznachrichten.de - August 21 at 11:39 PM
americanbankingnews.com logoBrokerages Anticipate G1 THERAPEUTICS (GTHX) to Post ($0.56) Earnings Per Share
www.americanbankingnews.com - August 17 at 12:36 PM
americanbankingnews.com logoQ3 2017 Earnings Estimate for G1 THERAPEUTICS Issued By Wedbush (GTHX)
www.americanbankingnews.com - August 14 at 2:52 AM
americanbankingnews.com logoHead-To-Head Comparison: G1 THERAPEUTICS (GTHX) vs. AVEO Pharmaceuticals (AVEO)
www.americanbankingnews.com - August 11 at 4:58 PM
americanbankingnews.com logoG1 THERAPEUTICS (NASDAQ:GTHX) to Post Q1 2018 Earnings of ($0.52) Per Share, Wedbush Forecasts
www.americanbankingnews.com - August 11 at 2:14 PM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Announces Quarterly Earnings Results, Misses Estimates By $0.48 EPS
www.americanbankingnews.com - August 10 at 9:52 PM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - August 9 at 9:10 PM
finance.yahoo.com logoG1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 9 at 7:29 PM
finance.yahoo.com logoG1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 7:01 PM
finance.yahoo.com logoG1 Therapeutics Makes Key Appointments to Management Team
finance.yahoo.com - August 3 at 7:16 PM
americanbankingnews.com logo Analysts Set $29.33 Price Target for G1 THERAPEUTICS (GTHX)
www.americanbankingnews.com - August 2 at 8:30 AM
finance.yahoo.com logoG1 Therapeutics, Inc. (Nasdaq: GTHX) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - August 1 at 7:51 PM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - July 30 at 6:22 PM
finance.yahoo.com logoG1 Therapeutics to Ring Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017
finance.yahoo.com - July 27 at 7:51 PM
americanbankingnews.com logoZacks: G1 THERAPEUTICS (NASDAQ:GTHX) Receives Average Rating of "" from Brokerages
www.americanbankingnews.com - July 18 at 5:02 PM
finance.yahoo.com logoG1 Therapeutics Appoints Sir Andrew Witty to Board of Directors
finance.yahoo.com - July 14 at 2:46 AM
americanbankingnews.com logoZacks: Analysts Anticipate G1 THERAPEUTICS (GTHX) Will Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - July 6 at 2:30 PM
americanbankingnews.com logoBrokerages Anticipate G1 THERAPEUTICS (GTHX) to Announce ($0.82) EPS
www.americanbankingnews.com - July 3 at 10:40 AM
finance.yahoo.com logoWith IPO under its belt, important milestones on the horizon for G1 Therapeutics
finance.yahoo.com - June 28 at 6:54 PM
americanbankingnews.com logoG1 THERAPEUTICS's Quiet Period To End on June 26th (NASDAQ:GTHX)
www.americanbankingnews.com - June 19 at 8:12 AM
americanbankingnews.com logoZacks: G1 THERAPEUTICS (GTHX) Given $29.75 Consensus Price Target by Brokerages
www.americanbankingnews.com - June 14 at 11:08 AM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Coverage Initiated at Needham & Company LLC
www.americanbankingnews.com - June 12 at 3:38 PM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Research Coverage Started at Wedbush
www.americanbankingnews.com - June 12 at 9:38 AM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Research Coverage Started at Cowen and Company
www.americanbankingnews.com - June 12 at 9:16 AM
americanbankingnews.com logoG1 THERAPEUTICS (GTHX) Now Covered by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - June 12 at 9:16 AM
streetinsider.com logoJPMorgan Starts G1 Therapeutics (GTHX) at Overweight
www.streetinsider.com - June 12 at 3:46 AM
finance.yahoo.com logoRetail Investors: Your IPOs Are Here
finance.yahoo.com - June 9 at 6:00 PM
finance.yahoo.com logoG1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 30 at 10:56 AM
finance.yahoo.com logoG1 Therapeutics, Inc. (GTHX)
finance.yahoo.com - May 27 at 5:55 PM
finance.yahoo.com logoIPOs This Week: Software Maker Appian Plus 3 More Hopefuls
finance.yahoo.com - May 25 at 10:55 AM
finance.yahoo.com logoG1 Therapeutics Announces Closing of Initial Public Offering
finance.yahoo.com - May 25 at 10:55 AM
americanbankingnews.com logoG1 Therapeutics Inc (GTHX) Major Shareholder Buys $1,999,995.00 in Stock
www.americanbankingnews.com - May 24 at 10:14 PM
americanbankingnews.com logoRa Capital Healthcare Fund Lp Acquires 400,000 Shares of G1 Therapeutics Inc (GTHX) Stock
www.americanbankingnews.com - May 24 at 10:14 PM
americanbankingnews.com logoG1 Therapeutics Inc (GTHX) Director Fredric N. Eshelman Purchases 300,000 Shares
www.americanbankingnews.com - May 24 at 10:14 PM
americanbankingnews.com logoG1 Therapeutics (GTHX) Plans to Raise $101 Million in May 17th IPO
www.americanbankingnews.com - May 9 at 10:20 AM

Social

Chart

G1 THERAPEUTICS (GTHX) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff